{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:41:10Z","timestamp":1790754070651,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.bulcan.2018.06.008","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T12:29:17Z","timestamp":1533904157000},"page":"790-803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Suivi th\u00e9rapeutique pharmacologique du 5-fluorouracile\u00a0: mise au point et recommandations du groupe STP-PT de la SFPT et du GPCO-Unicancer"],"prefix":"10.1016","volume":"105","author":[{"given":"Florian","family":"Lemaitre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Goirand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Chatelut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Evrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Noelle","family":"Paludetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Guilhaumou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ciccolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-7730","authenticated-orcid":false,"given":"Antonin","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bulcan.2018.06.008_bib0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.COC.0000017526.55135.6D","article-title":"Severe toxicity related to the 5-fluorouracil\/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients","volume":"26","author":"Tsalic","year":"2003","journal-title":"Am J Clin Oncol"},{"issue":"16","key":"10.1016\/j.bulcan.2018.06.008_bib0010","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2018.06.008_bib0015","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/bjc.2017.94","article-title":"Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity","volume":"116","author":"Meulendijks","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2018.06.008_bib0020","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.critrevonc.2017.08.006","article-title":"Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis","volume":"118","author":"Marques","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.bulcan.2018.06.008_bib0025","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","article-title":"Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks","volume":"105","author":"Loriot","year":"2018","journal-title":"Bull Cancer (Paris)"},{"issue":"3","key":"10.1016\/j.bulcan.2018.06.008_bib0030","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1124\/dmd.114.061820","article-title":"Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis?","volume":"43","author":"Zhang","year":"2015","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"6","key":"10.1016\/j.bulcan.2018.06.008_bib0035","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-008-0838-z","article-title":"Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer","volume":"63","author":"Yuan","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.bulcan.2018.06.008_bib0040","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0895-3988(08)60044-6","article-title":"Breast cancer resistance protein expression and 5-fluorouracil resistance","volume":"21","author":"Yuan","year":"2008","journal-title":"Biomed Environ Sci BES"},{"issue":"16","key":"10.1016\/j.bulcan.2018.06.008_bib0045","first-page":"3537","article-title":"Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines","volume":"57","author":"Kool","year":"1997","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.bulcan.2018.06.008_bib0050","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3390\/cancers3010106","article-title":"Membrane drug transporters and chemoresistance in human pancreatic carcinoma","volume":"3","author":"Hagmann","year":"2010","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.bulcan.2018.06.008_bib0055","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF00543978","article-title":"Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients","volume":"32","author":"Schaaf","year":"1987","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.bulcan.2018.06.008_bib0060","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.1992.10.7.1171","article-title":"Influence of sex and age on fluorouracil clearance","volume":"10","author":"Milano","year":"1992","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2018.06.008_bib0065","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.bulcan.2018.06.008_bib0070","doi-asserted-by":"crossref","first-page":"11559","DOI":"10.18632\/oncotarget.24338","article-title":"5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer","volume":"9","author":"Morawska","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bulcan.2018.06.008_bib0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0959-8049(97)00345-6","article-title":"Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis","volume":"34","author":"Etienne","year":"1998","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"4","key":"10.1016\/j.bulcan.2018.06.008_bib0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jama.1962.03050300015003","article-title":"Five years clinical experience with 5-fluorouracil","volume":"181","author":"Ansfield","year":"1962","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.bulcan.2018.06.008_bib0085","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/bjc.1992.335","article-title":"No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion","volume":"66","author":"Fleming","year":"1992","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2018.06.008_bib0090","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1067\/mcp.2000.109352","article-title":"Dose and time dependencies of 5-fluorouracil pharmacokinetics","volume":"68","author":"Terret","year":"2000","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bulcan.2018.06.008_bib0095","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","article-title":"Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage","volume":"17","author":"Gamelin","year":"1999","journal-title":"J Clin Oncol"},{"issue":"Suppl. 5","key":"10.1016\/j.bulcan.2018.06.008_bib0100","article-title":"Pharmacokinetic (PK)-guided optimization of 5-fluorouracil (5FU) exposure in colorectal cancer (CRC) patients: U.S.-based clinical practices experience","volume":"32","author":"Braiteh","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2018.06.008_bib0105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clcc.2011.03.015","article-title":"Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens","volume":"10","author":"Saam","year":"2011","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2018.06.008_bib0110","first-page":"1145","article-title":"A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5\u00a0days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel","volume":"13","author":"Ismail","year":"2005","journal-title":"Oncol Rep"},{"issue":"2","key":"10.1016\/j.bulcan.2018.06.008_bib0115","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002800000189","article-title":"Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion","volume":"47","author":"Grem","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.bulcan.2018.06.008_bib0120","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/02841860214959","article-title":"Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer","volume":"41","author":"Jakobsen","year":"2002","journal-title":"Acta Oncol Stockh Swed"},{"issue":"9","key":"10.1016\/j.bulcan.2018.06.008_bib0125","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00228-002-0534-6","article-title":"Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report","volume":"58","author":"Bocci","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.bulcan.2018.06.008_bib0130","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1053\/ajkd.2002.30584","article-title":"Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis","volume":"39","author":"Rengelshausen","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1016\/j.bulcan.2018.06.008_bib0135","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/annonc\/mdl284","article-title":"Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181\u00a0patients on adjuvant therapy for colorectal cancer","volume":"17","author":"Gusella","year":"2006","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2018.06.008_bib0140","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1634\/theoncologist.2014-0132","article-title":"A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy","volume":"19","author":"Patel","year":"2014","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.bulcan.2018.06.008_bib0145","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s40262-016-0395-2","article-title":"Pharmacokinetic and pharmacodynamic analyses of 5-fluorouracil in East-Asian patients with nasopharyngeal carcinoma","volume":"55","author":"Ma","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.bulcan.2018.06.008_bib0150","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clcc.2012.05.004","article-title":"Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study","volume":"11","author":"Capitain","year":"2012","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2018.06.008_bib0155","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00280-003-0658-0","article-title":"Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2\u00a0regimen","volume":"52","author":"Ychou","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.bulcan.2018.06.008_bib0160","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO;2-N","article-title":"Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU","volume":"77","author":"Gamelin","year":"1996","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2018.06.008_bib0165","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5414\/CPP51056","article-title":"5-FU schedules, serum 5-FU levels and their relationship to therapy response and toxicity in patients with gastrointestinal cancer","volume":"51","author":"Blaschke","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.bulcan.2018.06.008_bib0170","first-page":"2039","article-title":"Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas","volume":"4","author":"Fety","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.bulcan.2018.06.008_bib0175","first-page":"1","article-title":"Special report: laboratory testing to allow area under the curve (AUC)-targeted 5-fluorouracil dosing for patients administered chemotherapy for cancer","volume":"24","year":"2010","journal-title":"Technol Eval Cent Assess Program Exec Summ"},{"issue":"15","key":"10.1016\/j.bulcan.2018.06.008_bib0180","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2174\/156802612803531414","article-title":"Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity","volume":"12","author":"Woloch","year":"2012","journal-title":"Curr Top Med Chem"},{"issue":"6","key":"10.1016\/j.bulcan.2018.06.008_bib0185","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/bjc.1978.278","article-title":"Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion","volume":"38","author":"Hillcoat","year":"1978","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2018.06.008_bib0190","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.1997.15.2.808","article-title":"Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study","volume":"15","author":"de Gramont","year":"1997","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.bulcan.2018.06.008_bib0195","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2018.06.008_bib0200","first-page":"439","article-title":"Pharmacokinetic monitoring with dosage adjustment of 5\u00a0fluorouracil administered by continuous infusion","volume":"80","author":"Wihlm","year":"1993","journal-title":"Bull Cancer (Paris)"},{"issue":"7","key":"10.1016\/j.bulcan.2018.06.008_bib0205","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4161\/cbt.12.7.18059","article-title":"Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients","volume":"12","author":"Kline","year":"2011","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"10.1016\/j.bulcan.2018.06.008_bib0210","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clcc.2013.11.001","article-title":"Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5\u2013fluorouracil-based chemotherapy regimens","volume":"13","author":"Kline","year":"2014","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2018.06.008_bib0215","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bjc.1989.59","article-title":"5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer","volume":"59","author":"Santini","year":"1989","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2018.06.008_bib0220","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1998.16.4.1470","article-title":"Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152\u00a0patients","volume":"16","author":"Gamelin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2018.06.008_bib0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.clcc.2016.04.001","article-title":"Prospective, multicenter study of 5-fluorouracil therapeutic drug monitoring in metastatic colorectal cancer treated in routine clinical practice","author":"Wilhelm","year":"2016","journal-title":"Clin Colorectal Cancer [Internet]"},{"issue":"13","key":"10.1016\/j.bulcan.2018.06.008_bib0230","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2018.06.008_bib0235","doi-asserted-by":"crossref","first-page":"A139","DOI":"10.1016\/j.jval.2013.03.680","article-title":"Cost-effectiveness of pharmacokinetic dosing of 5-fluorouracil in metastatic colorectal cancer in the United Kingdom","volume":"16","author":"Becker","year":"2013","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.bulcan.2018.06.008_bib0240","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clcc.2014.09.007","article-title":"Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer","volume":"13","author":"Goldstein","year":"2014","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2018.06.008_bib0245","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/BF00255288","article-title":"Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer","volume":"16","author":"Thyss","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.bulcan.2018.06.008_bib0250","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.1994.12.6.1291","article-title":"Relationship between fluorouracil systemic exposure and tumor response and patient survival","volume":"12","author":"Milano","year":"1994","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2018.06.008_bib0255","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2125.2007.02951.x","article-title":"Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy","volume":"64","author":"Beneton","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.bulcan.2018.06.008_bib0260","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1634\/theoncologist.2011-0357","article-title":"Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6","volume":"17","author":"Kaldate","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2018.06.008_bib0265","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 - Diffuseurs portables [Internet]. [cited 2018\u00a0Apr 18]. Available from: https:\/\/www.has-sante.fr\/portail\/jcms\/c_398549\/fr\/diffuseurs-portables."},{"issue":"3","key":"10.1016\/j.bulcan.2018.06.008_bib0270","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2515\/therapie\/2010023","article-title":"Niveau de preuve du suivi th\u00e9rapeutique pharmacologique du 5-fluorouracile au d\u00e9cours de son administration dans le traitement des cancers des voies a\u00e9rodigestives sup\u00e9rieures et du cancer colorectal","volume":"65","author":"Boisdron-Celle","year":"2010","journal-title":"Therapie"},{"issue":"6","key":"10.1016\/j.bulcan.2018.06.008_bib0275","first-page":"1676","article-title":"Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients","volume":"48","author":"Petit","year":"1988","journal-title":"Cancer Res"},{"issue":"21","key":"10.1016\/j.bulcan.2018.06.008_bib0280","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/jnci\/86.21.1608","article-title":"Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial","volume":"86","author":"L\u00e9vi","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"69","key":"10.1016\/j.bulcan.2018.06.008_bib0285","article-title":"Circadian variation in plasma 5-fluorouracil concentrations during a 24\u00a0hour constant-rate infusion","volume":"15","author":"Fleming","year":"2015","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2018.06.008_bib0290","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/bcp.13007","article-title":"Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers","volume":"82","author":"Jacobs","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.bulcan.2018.06.008_bib0295","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1093\/clinchem\/33.12.2299","article-title":"Stability of 5-fluorouracil in whole blood and plasma","volume":"33","author":"Murphy","year":"1987","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.bulcan.2018.06.008_bib0300","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0378-4347(97)00211-9","article-title":"Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma","volume":"695","author":"Gamelin","year":"1997","journal-title":"J Chromatogr B Biomed Sci App"},{"issue":"6","key":"10.1016\/j.bulcan.2018.06.008_bib0305","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jms.1759","article-title":"An APCI LC-MS\/MS method for routine determination of capecitabine and its metabolites in human plasma","volume":"45","author":"Montange","year":"2010","journal-title":"J Mass Spectrom JMS"},{"key":"10.1016\/j.bulcan.2018.06.008_bib0310","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jchromb.2015.03.002","article-title":"Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry","volume":"989","author":"Deng","year":"2015","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.bulcan.2018.06.008_bib0315","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jpba.2016.07.027","article-title":"LC-MS\/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma","volume":"129","author":"Holleran","year":"2016","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.bulcan.2018.06.008_bib0320","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jpba.2017.04.055","article-title":"Development, validation and application of a novel liquid chromatography tandem mass spectrometry assay measuring uracil, 5,6-dihydrouracil, 5-fluorouracil, 5,6-dihydro-5-fluorouracil, \u03b1-fluoro-\u03b2-ureidopropionic acid and \u03b1-fluoro-\u03b2-alanine in human plasma","volume":"142","author":"Chavani","year":"2017","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"10.1016\/j.bulcan.2018.06.008_bib0325","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/FTD.0b013e3181b9b8c0","article-title":"Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400\u00a0analyzer","volume":"31","author":"Beumer","year":"2009","journal-title":"Ther Drug Monit"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118301954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118301954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T03:32:13Z","timestamp":1720495933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455118301954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0007455118301954"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.06.008","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suivi th\u00e9rapeutique pharmacologique du 5-fluorouracile\u00a0: mise au point et recommandations du groupe STP-PT de la SFPT et du GPCO-Unicancer","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}